Anemia, Mortality, and Hospitalizations in Heart Failure with a Preserved Ejection Fraction (From the TOPCAT Trial)

Abstract In this post-hoc analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, we evaluated the prognostic role of anemia in adverse cardiovascular (CV) outcomes in heart failure with a preserved ejection fraction (HFpEF). We defined anemia as hemoglobin of 0.05) as compared to those without anemia. Among CV causes, patients with anemia had a higher risk of sudden cardiac death (SCD)/ACA and presumed CV death (HR 1.67 and 1.83, respectively, p 0.05). Among non-CV causes, patients with anemia had a higher risk of death due to malignancy (HR 2.61, p